Clinical trial
Analysis of the Duration of Combination Therapy That is Necessary for HCV…
NCT00152581 · University College London Hospitals, Other · Completed
Key facts
| NCT number | NCT00152581 |
|---|---|
| Title | Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication |
| Official title | Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication |
| Lead sponsor | University College London Hospitals, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C, HCV Genotype 1 |
| Intervention type | Drug |
| Interventions | Pegylated interferon-alfa2a (Pegasys), ribavirin |
| Enrollment | 40 |
| Start date | Apr 1, 2002 |
| First posted | Sep 9, 2005 |
| Last update posted | Dec 1, 2005 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: